S&P 500   4,564.57 (-0.65%)
DOW   36,192.36 (-0.15%)
QQQ   385.28 (-1.20%)
AAPL   188.96 (-1.19%)
MSFT   368.19 (-1.69%)
META   317.78 (-2.17%)
GOOGL   128.56 (-2.50%)
AMZN   144.33 (-1.84%)
TSLA   237.08 (-0.73%)
NVDA   452.72 (-3.19%)
NIO   7.32 (+2.38%)
BABA   73.07 (-1.24%)
AMD   118.46 (-2.41%)
T   16.58 (-1.07%)
F   10.68 (+0.95%)
MU   74.08 (-2.44%)
CGC   0.73 (+18.85%)
GE   121.71 (-0.64%)
DIS   92.04 (-0.58%)
AMC   7.35 (+7.14%)
PFE   29.35 (+1.52%)
PYPL   59.97 (+0.54%)
XOM   102.47 (-0.50%)
S&P 500   4,564.57 (-0.65%)
DOW   36,192.36 (-0.15%)
QQQ   385.28 (-1.20%)
AAPL   188.96 (-1.19%)
MSFT   368.19 (-1.69%)
META   317.78 (-2.17%)
GOOGL   128.56 (-2.50%)
AMZN   144.33 (-1.84%)
TSLA   237.08 (-0.73%)
NVDA   452.72 (-3.19%)
NIO   7.32 (+2.38%)
BABA   73.07 (-1.24%)
AMD   118.46 (-2.41%)
T   16.58 (-1.07%)
F   10.68 (+0.95%)
MU   74.08 (-2.44%)
CGC   0.73 (+18.85%)
GE   121.71 (-0.64%)
DIS   92.04 (-0.58%)
AMC   7.35 (+7.14%)
PFE   29.35 (+1.52%)
PYPL   59.97 (+0.54%)
XOM   102.47 (-0.50%)
S&P 500   4,564.57 (-0.65%)
DOW   36,192.36 (-0.15%)
QQQ   385.28 (-1.20%)
AAPL   188.96 (-1.19%)
MSFT   368.19 (-1.69%)
META   317.78 (-2.17%)
GOOGL   128.56 (-2.50%)
AMZN   144.33 (-1.84%)
TSLA   237.08 (-0.73%)
NVDA   452.72 (-3.19%)
NIO   7.32 (+2.38%)
BABA   73.07 (-1.24%)
AMD   118.46 (-2.41%)
T   16.58 (-1.07%)
F   10.68 (+0.95%)
MU   74.08 (-2.44%)
CGC   0.73 (+18.85%)
GE   121.71 (-0.64%)
DIS   92.04 (-0.58%)
AMC   7.35 (+7.14%)
PFE   29.35 (+1.52%)
PYPL   59.97 (+0.54%)
XOM   102.47 (-0.50%)
S&P 500   4,564.57 (-0.65%)
DOW   36,192.36 (-0.15%)
QQQ   385.28 (-1.20%)
AAPL   188.96 (-1.19%)
MSFT   368.19 (-1.69%)
META   317.78 (-2.17%)
GOOGL   128.56 (-2.50%)
AMZN   144.33 (-1.84%)
TSLA   237.08 (-0.73%)
NVDA   452.72 (-3.19%)
NIO   7.32 (+2.38%)
BABA   73.07 (-1.24%)
AMD   118.46 (-2.41%)
T   16.58 (-1.07%)
F   10.68 (+0.95%)
MU   74.08 (-2.44%)
CGC   0.73 (+18.85%)
GE   121.71 (-0.64%)
DIS   92.04 (-0.58%)
AMC   7.35 (+7.14%)
PFE   29.35 (+1.52%)
PYPL   59.97 (+0.54%)
XOM   102.47 (-0.50%)

Zynerba Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ZYNE)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.26
$1.34
50-Day Range
$1.21
$1.39
52-Week Range
$0.25
$1.40
Volume
862,700 shs
Average Volume
515,333 shs
Market Capitalization
$70.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.11

Zynerba Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
14.6% Downside
$1.11 Price Target
Short Interest
Healthy
25.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$64,033 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.84) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.09 out of 5 stars

Medical Sector

933rd out of 951 stocks

Pharmaceutical Preparations Industry

431st out of 438 stocks


ZYNE stock logo

About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.


ZYNE Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
20 Countries With Highest Rate of Epilepsy
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher
See More Headlines
Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2023
Today
12/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZYNE
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.11
High Stock Price Target
$1.11
Low Stock Price Target
$1.11
Potential Upside/Downside
-14.6%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-35,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.01 per share

Miscellaneous

Free Float
46,905,000
Market Cap
$70.12 million
Optionable
Optionable
Beta
1.32
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Armando Anido MBA (Age 65)
    Chairman & CEO
    Comp: $934.53k
  • Ms. Terri B. Sebree (Age 65)
    Pres
    Comp: $729.15k
  • Mr. James E. Fickenscher (Age 59)
    CFO & VP of Corp. Devel. (Leave of Absence)
    Comp: $607.62k
  • Mr. Kenneth T. Jones (Age 59)
    VP, Corp. Controller & Interim CFO
  • Mr. Albert P. Parker II (Age 57)
    Chief Legal Officer & Corp. Sec.
  • Mr. Joseph Apostolico
    VP of HR














ZYNE Stock Analysis - Frequently Asked Questions

Should I buy or sell Zynerba Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZYNE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYNE, but not buy additional shares or sell existing shares.
View ZYNE analyst ratings
or view top-rated stocks.

What is Zynerba Pharmaceuticals' stock price target for 2024?

4 brokers have issued 1 year price objectives for Zynerba Pharmaceuticals' shares. Their ZYNE share price targets range from $1.11 to $1.11. On average, they expect the company's share price to reach $1.11 in the next twelve months. This suggests that the stock has a possible downside of 14.6%.
View analysts price targets for ZYNE
or view top-rated stocks among Wall Street analysts.

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) posted its earnings results on Monday, May, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.02.

What ETF holds Zynerba Pharmaceuticals' stock ?

Amplify Seymour Cannabis ETF holds 220,858 shares of ZYNE stock, representing 0.30% of its portfolio.

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Beryl Capital Management LLC (9.08%), Deltec Asset Management LLC (0.88%), GTS Securities LLC (0.22%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armando Anido, Brian Rosenberger, Daniel L Kisner, James E Fickenscher, Kenneth T Jones, Pamela Stephenson and Terri B Sebree.
View institutional ownership trends
.

This page (NASDAQ:ZYNE) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -